Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

408 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
New molecular targets in melanoma.
Flaherty KT. Flaherty KT. Curr Opin Oncol. 2004 Mar;16(2):150-4. doi: 10.1097/00001622-200403000-00012. Curr Opin Oncol. 2004. PMID: 15075908 Review.
VEGFR-targeted therapy.
Flaherty KT. Flaherty KT. Clin Adv Hematol Oncol. 2005 May;3(5):371-2. Clin Adv Hematol Oncol. 2005. PMID: 16167010 No abstract available.
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ. Vonderheide RH, et al. Among authors: flaherty kt. J Clin Oncol. 2007 Mar 1;25(7):876-83. doi: 10.1200/JCO.2006.08.3311. J Clin Oncol. 2007. PMID: 17327609 Clinical Trial.
Targeted therapy for metastatic melanoma.
Amaravadi RK, Flaherty KT. Amaravadi RK, et al. Among authors: flaherty kt. Clin Adv Hematol Oncol. 2007 May;5(5):386-94. Clin Adv Hematol Oncol. 2007. PMID: 17673894 No abstract available.
The MAPK pathway in melanoma.
Fecher LA, Amaravadi RK, Flaherty KT. Fecher LA, et al. Among authors: flaherty kt. Curr Opin Oncol. 2008 Mar;20(2):183-9. doi: 10.1097/CCO.0b013e3282f5271c. Curr Opin Oncol. 2008. PMID: 18300768 Review.
408 results